Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) Director Sells $84,742.28 in Stock

United Therapeutics Co. (NASDAQ:UTHR) Director Nilda Mesa sold 266 shares of the stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total transaction of $84,742.28. Following the completion of the sale, the director now directly owns 5,107 shares of the company’s stock, valued at $1,626,988.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

United Therapeutics Stock Up 0.5 %

Shares of NASDAQ:UTHR opened at $318.55 on Friday. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $321.80. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.64 and a current ratio of 3.77. The company’s fifty day moving average is $274.77 and its 200-day moving average is $244.09. The company has a market capitalization of $14.13 billion, a PE ratio of 15.06, a P/E/G ratio of 1.39 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The business had revenue of $677.70 million during the quarter, compared to analysts’ expectations of $620.31 million. During the same period in the previous year, the business posted $4.86 earnings per share. The firm’s revenue for the quarter was up 33.7% compared to the same quarter last year. Equities research analysts predict that United Therapeutics Co. will post 24.73 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on UTHR shares. Oppenheimer raised their price objective on shares of United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 20th. The Goldman Sachs Group raised their price objective on shares of United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $325.00 to $350.00 and gave the company an “overweight” rating in a research report on Wednesday, June 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a research report on Thursday, May 2nd. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $312.22.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Blue Trust Inc. raised its holdings in shares of United Therapeutics by 10.0% in the fourth quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 46 shares during the last quarter. MBM Wealth Consultants LLC raised its holdings in United Therapeutics by 2.7% during the 1st quarter. MBM Wealth Consultants LLC now owns 2,241 shares of the biotechnology company’s stock worth $515,000 after purchasing an additional 59 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in United Therapeutics by 1.6% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 3,892 shares of the biotechnology company’s stock worth $856,000 after purchasing an additional 61 shares during the last quarter. Janiczek Wealth Management LLC raised its holdings in United Therapeutics by 21.1% during the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after purchasing an additional 84 shares during the last quarter. Finally, Compass Ion Advisors LLC raised its holdings in United Therapeutics by 3.6% during the 1st quarter. Compass Ion Advisors LLC now owns 2,892 shares of the biotechnology company’s stock worth $664,000 after purchasing an additional 101 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.